Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Drug Evaluation Research ; 43(4):601-605, 2020.
Article in Chinese | GIM | ID: covidwho-1352918

ABSTRACT

New coronavirus pneumonia is menacing, and patients with new coronavirus pneumonia combined with other underlying diseases are more at risk. Glycemic control level directly affects the body's immune response and body state. Its low immune status is extremely likely to increase the risk of illness. Infected patients are more likely to aggravate the infection and further cause cytokine storms. Therefore, patients with new type of coronavirus infection and type 2 diabetes need better blood glucose control and management while treating new type of coronavirus infection. This article combines the research on the rational use of diabetes and analyzes the characteristics of the existing clinical data of COVID-19 to explore the pharmacological practice mode and medication monitoring strategy of this special patient. It is hoped to provide COVID-19 patients with diabetes with a more optimized and reasonable medication regimen and improve the clinical medication level.

SELECTION OF CITATIONS
SEARCH DETAIL